drugset / Trial / NCT05210374
Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety of combining the disulfiram (DSF) and copper gluconate (Cu) to liposomal doxorubicin to treat patients with sarcomas that recurred or did not respond to initial treatment.
Timeline
- Start
- 2023-03-09
- Primary completion
- 2026-09-01
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disulfiram | Small molecule | 150 mg/m2 | Oral |
| Subject | Disulfiram | Small molecule | 225 mg/m2 | Oral |
| Subject | Disulfiram | Small molecule | 300 mg/m2 | Oral |
| Background | Copper Gluconate | Small molecule | 5.2 mg/m2 | Oral |
| Background | Doxorubicin | Other / unclassified | 30 mg/m2 | Intravenous |